Prognostic Factor Risk Groups for Clinical Stage I Seminoma: An Individual Patient Data Analysis by the European Association of Urology Testicular Cancer Guidelines Panel and Guidelines Office.

Boormans, Joost L; Sylvester, Richard; Anson-Cartwright, Lynn; Glicksman, Rachel M; Hamilton, Robert J; Hahn, Ezra; Daugaard, Gedske; Lauritsen, Jakob; Wagner, Thomas; Avuzzi, Barbara; Nicolai, Nicola; Del Muro, Xavier García; Aparicio, Jorge; Stalder, Odile; Rothermundt, Christian; Fischer, Stefanie; Laguna, M Pilar (2024). Prognostic Factor Risk Groups for Clinical Stage I Seminoma: An Individual Patient Data Analysis by the European Association of Urology Testicular Cancer Guidelines Panel and Guidelines Office. European urology oncology, 7(3), pp. 537-543. Elsevier 10.1016/j.euo.2023.10.014

Text Boormans_EurUrolOncol_2023_epub.pdf - Published Version Restricted to registered users only Available under License Publisher holds Copyright. Download (800kB)

BACKGROUND

The relapse rate in patients with clinical stage I (CSI) seminomatous germ cell tumor of the testis (SGCTT) who were undergoing surveillance after radical orchidectomy is 4-30%, depending on tumor size and rete testis invasion (RTI). However, the level of evidence supporting the use of both risk factors in clinical decision-making is low.

OBJECTIVE

We aimed to identify the most important prognostic factors for relapse in CSI SGCTT patients.

DESIGN, SETTING, AND PARTICIPANTS

Individual patient data for 1016 CSI SGCTT patients diagnosed between 1994 and 2019 with normal postorchidectomy serum tumor marker levels and undergoing surveillance were collected from nine institutions.

OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS

Multivariable Cox proportional hazard regression models were fit to identify the most important prognostic factors. The primary endpoint was the time to first relapse by imaging and/or markers. Relapse probabilities were estimated by the Kaplan-Meier method.

RESULTS AND LIMITATIONS

After a median follow-up of 7.7 yr, 149 (14.7%) patients had relapsed. Categorical tumor size (≤2, >2-5, and >5 cm), presence of RTI, and lymphovascular invasion were used to form three risk groups: low (56.4%), intermediate (41.3%), and high (2.3%) risks with 5-yr cumulative relapse probabilities of 8%, 20%, and 44%, respectively. The model outperformed the currently used model with tumor size ≤4 versus >4 cm and presence of RTI (Harrell's C index 0.65 vs 0.61). The low- and intermediate-risk groups were validated successfully in an independent cohort of 285 patients.

CONCLUSIONS

The risk of relapse after radical orchidectomy in CSI SGCTT patients under surveillance is low. We propose a new risk stratification model that outperformed the current model and identified a small subgroup with a high risk of relapse.

PATIENT SUMMARY

The risk of relapse after radical orchidectomy in patients with clinical stage I seminomatous germ cell tumor of the testis is low. We propose a new risk stratification model that outperformed the current model and identified a small subgroup with a high risk of relapse.

Interest & Impact

Downloads

5 since deposited on 14 Nov 2023
5 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item